{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:48:24Z","timestamp":1792835304524,"version":"4.5.0"},"reference-count":252,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is the most common autosomal dominant neurodegenerative disorder, characterized by a triad of motor dysfunction, cognitive decline, and psychiatric disturbances. While recent efforts have focused on developing disease-modifying therapies, no treatment has yet demonstrated clinical efficacy. As a result, symptomatic treatment remains the cornerstone of care. However, high-quality evidence from large randomized trials is limited, and therapeutic decisions must rely on clinical expertise and extrapolation from other neurological or psychiatric conditions. This narrative review provides a comprehensive and practical overview of symptomatic treatment strategies for HD with emphasis on the pathophysiological underpinnings of each symptom and the molecular mechanisms of available and emerging therapies, aiming to support rational, individualized management. Finally, we highlight the critical role of non-pharmacological interventions and the need for multidisciplinary approaches to optimize patient outcomes and quality of life.<\/jats:p>","DOI":"10.3390\/ijms26136220","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:28Z","timestamp":1751347708000},"page":"6220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Update on the Symptomatic Treatment of Huntington\u2019s Disease: From Pathophysiology to Clinical Practice"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4864-5548","authenticated-orcid":false,"given":"Gonzalo","family":"Olmedo-Saura","sequence":"first","affiliation":[{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques-Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain"},{"name":"European Huntington\u2019s Disease Network (EHDN), 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4400-9326","authenticated-orcid":false,"given":"Eugenio","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Bojtos","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques-Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain"},{"name":"European Huntington\u2019s Disease Network (EHDN), 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-7249","authenticated-orcid":false,"given":"Sa\u00fcl","family":"Mart\u00ednez-Horta","sequence":"additional","affiliation":[{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques-Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain"},{"name":"European Huntington\u2019s Disease Network (EHDN), 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-704X","authenticated-orcid":false,"given":"Javier","family":"Pagonabarraga","sequence":"additional","affiliation":[{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques-Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-1431","authenticated-orcid":false,"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques-Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain"},{"name":"European Huntington\u2019s Disease Network (EHDN), 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques-Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain"},{"name":"European Huntington\u2019s Disease Network (EHDN), 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","article-title":"Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records","volume":"84","author":"Evans","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","article-title":"Prevalence and Incidence of Huntington\u2019s Disease: An Updated Systematic Review and Meta-Analysis","volume":"37","author":"Medina","year":"2022","journal-title":"Mov. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The Prevalence of Huntington\u2019s Disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Macdonald","year":"1993","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington Disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41591-024-03424-6","article-title":"Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington\u2019s disease decades before clinical motor diagnosis","volume":"31","author":"Scahill","year":"2025","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JHD-180292","article-title":"A Fresh Look at Huntingtin mRNA Processing in Huntington\u2019s Disease","volume":"7","author":"Romo","year":"2018","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease modifying therapies for Huntington\u2019s disease, lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: From molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: A genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of Genetic Factors that Modify Clinical Onset of Huntington\u2019s Disease","volume":"162","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"CAG Repeat Not Polyglutamine Length Determines Timing of Huntington\u2019s Disease Onset","volume":"178","author":"Lee","year":"2019","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cell.2024.11.038","article-title":"Long somatic DNA-repeat expansion drives neurodegeneration in Huntington\u2019s disease","volume":"188","author":"Handsaker","year":"2025","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-240017","article-title":"Huntington\u2019s Disease Clinical Trials Corner: March 2024","volume":"13","author":"Tabrizi","year":"2024","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.26014","article-title":"Current therapeutic options for Huntington\u2019s disease: Good clinical practice versus evidence-based approaches? Mov","volume":"29","author":"Killoran","year":"2014","journal-title":"Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1076\/0964-704X(200004)9:1;1-2;FT076","article-title":"George Huntington (1850\u20131916) and Hereditary Chorea","volume":"9","author":"Lanska","year":"2000","journal-title":"J. Hist. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rubinsztein, D.C. (2003). Molecular Biology of Huntington\u2019s Disease (HD) and HD-Like Disorders. Genetics of Movement Disorders, Elsevier.","DOI":"10.1016\/B978-012566652-7\/50035-6"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nguyen, H.H.P., and Cenci, M.A. (2015). The Neuropathology of Huntington\u2019s Disease. Behavioral Neurobiology of Huntington\u2019s Disease and Parkinson\u2019s Disease, Springer.","DOI":"10.1007\/978-3-662-46344-4"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(13)62418-6","article-title":"The expanding universe of disorders of the basal ganglia","volume":"384","author":"Obeso","year":"2014","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1371\/4f8606b742ef3","article-title":"The Prevalence of Juvenile Huntington\u2019s Disease: A Review of the Literature and Meta-Analysis","volume":"4","author":"Quarrell","year":"2012","journal-title":"PLoS Curr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JHD-231523","article-title":"Clinical Review of Juvenile Huntington\u2019s Disease","volume":"13","author":"Oosterloo","year":"2024","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/mds.28823","article-title":"Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review","volume":"37","author":"Bakels","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(18)30334-X","article-title":"Juvenile Huntington\u2019s disease: Left behind?","volume":"17","author":"Stout","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_28","unstructured":"Goldman, J.G. (2022). Principles and Practice of Movement Disorders, Elsevier. [3rd ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S1474-4422(09)70183-8","article-title":"Treatment of hyperkinetic movement disorders","volume":"8","author":"Jankovic","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bachoud-L\u00e9vi, A.-C., Ferreira, J., Massart, R., Youssov, K., Rosser, A., Busse, M., Craufurd, D., Reilmann, R., De Michele, G., and Rae, D. (2019). International Guidelines for the Treatment of Huntington\u2019s Disease. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00710"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/pgmj.2004.019356","article-title":"Chorea and related disorders","volume":"80","author":"Bhidayasiri","year":"2004","journal-title":"Postgrad. Med. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11910-010-0163-x","article-title":"Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntington\u2019s Disease","volume":"11","author":"Goodman","year":"2010","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archneur.1991.00530140106023","article-title":"The Effect of Sleep on the Dyskinetic Movements of Parkinson\u2019s Disease, Gilles de la Tourette Syndrome, Huntington\u2019s Disease, and Torsion Dystonia","volume":"48","author":"Fish","year":"1991","journal-title":"Arch. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/JHD-190381","article-title":"Awareness of Chorea in Huntington\u2019s Disease","volume":"9","author":"Hergert","year":"2020","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JHD-200410","article-title":"The Impact of Anosognosia on Clinical and Patient-Reported Assessments of Psychiatric Symptoms in Huntington\u2019s Disease","volume":"9","author":"Isaacs","year":"2020","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_36","unstructured":"Kandel, E.R., Schwartz, J.H., and Jessell, T.M. (2000). The basal ganglia. Principles of Neural Science, The McGraw-Hill Companies."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/jcbfm.2010.186","article-title":"External Globus Pallidus Stimulation Modulates Brain Connectivity in Huntington\u2019s Disease","volume":"31","author":"Ligot","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Burgunder, J.-M., Guttman, M., Perlman, S., Goodman, N., van Kammen, D.P., and Goodman, L. (2011). An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington\u2019s Disease. PLoS Curr., 3.","DOI":"10.1371\/currents.RRN1260"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.28855","article-title":"An MDS Evidence-Based Review on Treatments for Huntington\u2019s Disease","volume":"37","author":"Ferreira","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41586-023-06926-4","article-title":"Transport and inhibition mechanisms of human VMAT2","volume":"626","author":"Wu","year":"2023","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-6147(90)90318-3","article-title":"How reserpine and chlorpromazine act: The impact of key discoveries on the history of psychopharmacology","volume":"11","author":"Curzon","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"RP91973","DOI":"10.7554\/eLife.91973.4","article-title":"Structural mechanisms for VMAT2 inhibition by tetrabenazine","volume":"12","author":"Dalton","year":"2024","journal-title":"eLife"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107580","DOI":"10.1016\/j.pharmthera.2020.107580","article-title":"VMAT2 inhibitors for the treatment of hyperkinetic movement disorders","volume":"212","author":"Koch","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Huntington Study Group (2006). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 66, 366\u2013372.","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","article-title":"The Long-term Effect of Tetrabenazine in the Management of Huntington Disease","volume":"31","author":"Fasano","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington\u2019s Disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2021.1876666","article-title":"State-of-the-art pharmacological approaches to reduce chorea in Huntington\u2019s disease","volume":"22","author":"Gibson","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington\u2019s disease\u2013good clinical practice versus evidence-based guideline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Frank, S. (2009). Tetrabenazine as anti-chorea therapy in Huntington Disease: An open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol., 9.","DOI":"10.1186\/1471-2377-9-62"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","article-title":"Short-term effects of tetrabenazine on chorea associated with Huntington\u2019s disease","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/cpdd.882","article-title":"Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect","volume":"10","author":"Schneider","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Huntington Study Group, Frank, S., Testa, C.M., Stamler, D., Kayson, E., Davis, C., Edmondson, M.C., Kinel, S., Leavitt, B., and Oakes, D. (2016). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. JAMA, 316, 40\u201350.","DOI":"10.1001\/jama.2016.8655"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","article-title":"The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study","volume":"36","author":"Frank","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-024-01139-3","article-title":"Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease","volume":"39","author":"Frank","year":"2025","journal-title":"CNS Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Stimming","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2024.2445728","article-title":"Valbenazine for the treatment of chorea associated with Huntington\u2019s disease","volume":"26","author":"Patino","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine Versus Deutetrabenazine for Huntington\u2019s Disease: Twins or Distant Cousins?","volume":"4","author":"Rodrigues","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/mdc3.14230","article-title":"Medication Use and Treatment Indications in Huntington\u2019s Disease; Analyses from a Large Cohort","volume":"11","author":"Feleus","year":"2024","journal-title":"Mov. Disord. Clin. Pr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22188","article-title":"A Europe-wide assessment of current medication choices in Huntington\u2019s disease","volume":"23","author":"Priller","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0706743718777392","article-title":"Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis","volume":"63","author":"Martino","year":"2018","journal-title":"Can. J. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: A double-blind comparative study in the management of Huntington\u2019s chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr. Med Res. Opin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington\u2019s disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/00048677509159834","article-title":"A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington\u2019s Chorea","volume":"9","author":"Leonard","year":"1975","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.38.1.84","article-title":"Serum haloperidol concentration and choreiform movements in Huntington\u2019s disease","volume":"38","author":"Barr","year":"1988","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/WNL.35.10.1450","article-title":"The gait abnormality of Huntington\u2019s disease","volume":"35","author":"Koller","year":"1985","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/jnnp.47.8.848","article-title":"Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington\u2019s disease","volume":"47","author":"Girotti","year":"1984","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14737175.2016.1226134","article-title":"Antipsychotic drugs in Huntington\u2019s disease","volume":"17","author":"Unti","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_70","first-page":"1","article-title":"Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society)","volume":"5","author":"Saft","year":"2023","journal-title":"Neurol. Res. Pr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/hmg\/ddn033","article-title":"Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II","volume":"17","author":"Benchoua","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","article-title":"Risperidone and the Treatment of Psychiatric, Motor, and Cognitive Symptoms in Huntington\u2019s Disease","volume":"20","author":"Duff","year":"2008","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/YIC.0b013e3283407775","article-title":"Risperidone long-acting injection and Huntington\u2019s disease: Case series with significant psychiatric and behavioural symptoms","volume":"26","author":"Johnston","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mdc3.12706","article-title":"Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database","volume":"6","author":"Schultz","year":"2018","journal-title":"Mov. Disord. Clin. Pr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","article-title":"Risperidone in chorea and psychosis of Huntington\u2019s disease","volume":"9","author":"Erdemoglu","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"ref_76","first-page":"CD006455","article-title":"Cochrane Movement Disorders Group Therapeutic interventions for disease progression in Huntington\u2019s disease","volume":"2009","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","article-title":"Olanzapine and Huntington\u2019s Disease","volume":"21","author":"Bogelman","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0004-282X2004000600030","article-title":"Functional and motor response to low dose olanzapine in huntington\u2019s disease: Case report","volume":"62","author":"Laks","year":"2004","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington\u2019s Disease: An Open Label Study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jnnp.67.1.123","article-title":"The use of olanzapine for movement disorder in Huntington\u2019s disease: A first case report","volume":"67","author":"Dipple","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s Disease with Olanzapine and Valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1176\/appi.neuropsych.12040097","article-title":"Aripiprazole Treatment for Choreoathetoid and Psychotic Symptoms of Huntington\u2019s Disease","volume":"25","author":"Yavuz","year":"2013","journal-title":"J. Neuropsychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/appi.ajp.2008.08040503","article-title":"Aripiprazole Effects on Psychosis and Chorea in a Patient with Huntington\u2019s Disease","volume":"165","author":"Lin","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the symptoms of Huntington\u2019s disease: Preliminary results comparing aripiprazole and tetrabenazine","volume":"24","author":"Brusa","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","article-title":"Quetiapine in Huntington\u2019s disease: A first case report","volume":"249","author":"Bonelli","year":"2002","journal-title":"J. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/070674370404900617","article-title":"Quetiapine in the Management of Psychosis Secondary to Huntington\u2019s Disease: A Case Report","volume":"49","author":"Seitz","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"(1979). The trial use of clozapine for abnormal involuntary movement disorders. Am. J. Psychiatry, 136, 317\u2013320.","DOI":"10.1176\/ajp.136.3.317"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","article-title":"Clozapine versus placebo in Huntington\u2019s disease: A double blind randomised comparative study","volume":"63","author":"Siesling","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","article-title":"Amantadine: Reappraisal of the timeless diamond\u2014Target updates and novel therapeutic potentials","volume":"128","author":"Danysz","year":"2021","journal-title":"J. Neural Transm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A Randomized Trial of Amantadine in Huntington Disease","volume":"60","author":"Dewey","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington\u2019s disease","volume":"59","author":"Metman","year":"2002","journal-title":"Neurology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","article-title":"IV amantadine improves chorea in Huntington\u2019s disease An acute randomized, controlled study","volume":"60","author":"Lucetti","year":"2003","journal-title":"Neurology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"s83","DOI":"10.1007\/s100720200081","article-title":"Amantadine in Huntington\u2019s disease: Open-label video-blinded study","volume":"23","author":"Lucetti","year":"2002","journal-title":"Neurol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","article-title":"A pilot study of the clinical efficacy and safety of memantine for Huntington\u2019s disease","volume":"13","author":"Ondo","year":"2007","journal-title":"Park. Relat. Disord."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Huntington Study Group (2003). Dosage effects of riluzole in Huntington\u2019s disease: A multicenter placebo-controlled study. Neurology, 61, 1551\u20131556.","DOI":"10.1212\/01.WNL.0000096019.71649.2B"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington\u2019s disease (HD): An open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: A 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170267","article-title":"Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington\u2019s Disease","volume":"7","author":"Waters","year":"2018","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_100","first-page":"e95665","article-title":"Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice","volume":"2","author":"Geva","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington Disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","article-title":"The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models","volume":"18","author":"Naia","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): A phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1212\/WNL.0000000000208206","article-title":"Analyses of the Phase 3 Trial of Pridopidine\u2019s Outcome on Function in Huntington Disease (PROOF-HD) Demonstrates Efficacy in Participants Without Antidopaminergic Medications (S30.002)","volume":"102","author":"Geva","year":"2024","journal-title":"Neurology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40263-025-01171-x","article-title":"The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington\u2019s Disease","volume":"39","author":"Goldberg","year":"2025","journal-title":"CNS Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.wnf.0000186648.93612.a5","article-title":"Efficacy of Levetiracetam in Huntington Disease","volume":"28","author":"Sciruicchio","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/mds.21061","article-title":"Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington\u2019s disease","volume":"21","author":"Zesiewicz","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5694\/j.1326-5377.1976.tb140550.x","article-title":"Clonazepam in the treatment of choreiform activity","volume":"1","author":"Peiris","year":"1976","journal-title":"Med. J. Aust."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3171\/JNS\/2008\/109\/7\/0130","article-title":"Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus","volume":"109","author":"Biolsi","year":"2008","journal-title":"J. Neurosurg."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1007\/s10072-021-05527-1","article-title":"Deep brain stimulation in Huntington\u2019s disease: A literature review","volume":"42","author":"Bonomo","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mds.23967","article-title":"Deep brain stimulation in the treatment of chorea","volume":"27","author":"Edwards","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/mds.22116","article-title":"GPi-DBS in Huntington\u2019s disease: Results on motor function and cognition in a 72-year-old case","volume":"23","author":"Fasano","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3171\/2014.2.JNS131722","article-title":"Deep brain stimulation for Huntington\u2019s disease: Long-term results of a prospective open-label study","volume":"121","author":"Gonzalez","year":"2014","journal-title":"J. Neurosurg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.2009.202903","article-title":"Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington\u2019s disease","volume":"82","author":"Kang","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2013.11.007","article-title":"A 5-year follow-up of deep brain stimulation in Huntington\u2019s disease","volume":"20","author":"Moreno","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","article-title":"Bilateral globus pallidus stimulation for Huntington\u2019s disease","volume":"56","author":"Moro","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/mds.24959","article-title":"Deep brain stimulation in Huntington\u2019s disease: A 4-year follow-up case report","volume":"27","author":"Spielberger","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_118","first-page":"1","article-title":"GPi\/GPe borderland\u2013 a potential sweet spot for deep brain stimulation for chorea in Huntington\u2019s disease?","volume":"6","author":"Steinhardt","year":"2024","journal-title":"Neurol. Res. Pr."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Wojtecki, L., Groiss, S.J., Ferrea, S., Elben, S., Hartmann, C.J., Dunnett, S.B., Rosser, A., Saft, C., S\u00fcdmeyer, M., and Ohmann, C. (2015). A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington\u2019s Disease. Front. Neurol., 6.","DOI":"10.3389\/fneur.2015.00177"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00415-015-7968-0","article-title":"Deep brain stimulation of the internal pallidum in Huntington\u2019s disease patients: Clinical outcome and neuronal firing patterns","volume":"263","author":"Delorme","year":"2015","journal-title":"J. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/ene.12053","article-title":"The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington\u2019s disease: A pilot study","volume":"20","author":"Thompson","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/NPT.0000000000000016","article-title":"A Randomized Feasibility Study of a 12-Week Community-Based Exercise Program for People With Huntington\u2019s Disease","volume":"37","author":"Busse","year":"2013","journal-title":"J. Neurol. Phys. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.parkreldis.2022.06.013","article-title":"Physical activity and exercise outcomes in Huntington\u2019s disease (PACE-HD): Results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington\u2019s disease","volume":"101","author":"Quinn","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/bcp.15635","article-title":"A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington\u2019s disease","volume":"89","author":"Gamez","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7348","article-title":"Coordination of Prehensile Forces during Precision Grip in Huntington\u2019s Disease","volume":"163","author":"Gordon","year":"2000","journal-title":"Exp. Neurol."},{"key":"ref_126","first-page":"797","article-title":"Bringing order to higher order motor disorders","volume":"266","author":"Bhatia","year":"2018","journal-title":"J. Neurol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/mds.23243","article-title":"Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington\u2019s disease","volume":"25","author":"Reilmann","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.57.5.920","article-title":"Objective assessment of progression in Huntington\u2019s disease: A 3-year follow-up study","volume":"57","author":"Reilmann","year":"2001","journal-title":"Neurology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mdc3.12586","article-title":"The \u201cStutter-Step\u201d: A Peculiar Gait Feature in Advanced Huntington\u2019s Disease and Chorea-Acanthocytosis. Mov","volume":"5","author":"Termsarasab","year":"2018","journal-title":"Disord. Clin. Pract."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005053-195603000-00001","article-title":"Left hemiplegia and motor impersistence","volume":"123","author":"Fisher","year":"1956","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_131","first-page":"528","article-title":"Le syndrome frontal de la paralysie supranucl\u00e9aire progressive [Frontal syndrome of progressive supranuclear palsy]","volume":"141","author":"Cambier","year":"1985","journal-title":"Rev Neurol"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0010-9452(13)80271-7","article-title":"Motor Impersistence in Alzheimer\u2019s Disease","volume":"27","author":"Lopez","year":"1991","journal-title":"Cortex"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1073\/pnas.0611625104","article-title":"Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior","volume":"104","author":"Gantois","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"C218","DOI":"10.1152\/ajpcell.00153.2020","article-title":"Mechanisms of altered skeletal muscle action potentials in the R6\/2 mouse model of Huntington\u2019s disease","volume":"319","author":"Miranda","year":"2020","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00002826-199510000-00005","article-title":"Acute Challenge with Apomorphine in Huntington\u02bcs Disease","volume":"18","author":"Albanese","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/ene.13349","article-title":"Clinical characterization of dystonia in adult patients with Huntington\u2019s disease","volume":"24","author":"Massey","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1531-8257(199901)14:1<95::AID-MDS1016>3.0.CO;2-8","article-title":"Dystonia in Huntington\u2019s disease: Prevalence and clinical characteristics","volume":"14","author":"Louis","year":"1999","journal-title":"Mov Disord."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e01704","DOI":"10.1002\/brb3.1704","article-title":"Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic-rigid motor subtypes in Huntington\u2019s disease","volume":"10","author":"Achenbach","year":"2020","journal-title":"Brain Behav."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.36.2.160","article-title":"Torsion dystonia: A double-blind, prospective trial of high-dosage trihexyphenidyl","volume":"36","author":"Burke","year":"1986","journal-title":"Neurology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3171\/2013.11.PEDS13253","article-title":"Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience: Clinical article","volume":"13","author":"Motta","year":"2014","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_141","first-page":"1","article-title":"Dystonia","volume":"4","author":"Balint","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1468-1331.2010.03058.x","article-title":"Botulinum toxin for treatment of dystonia","volume":"17","author":"Dressler","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: State of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ner.12098","article-title":"Bilateral Globus Pallidus Stimulation in Westphal Variant of Huntington Disease","volume":"17","author":"Cislaghi","year":"2013","journal-title":"Neuromodul. Technol. Neural Interface"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00415-018-8880-1","article-title":"Pallidal deep brain stimulation in juvenile Huntington\u2019s disease: Local field potential oscillations and clinical data","volume":"265","author":"Ferrea","year":"2018","journal-title":"J. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/mdc3.14327","article-title":"An Open-Label Pilot Study to Examine the Safety, Tolerability and Efficacy of Deutetrabenazine in Isolated Dystonia","volume":"12","author":"Deik","year":"2025","journal-title":"Mov. Disord. Clin. Pr."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Reilmann, R. (2019). Parkinsonism in Huntington\u2019s disease. International Review of Neurobiology, Elsevier.","DOI":"10.1016\/bs.irn.2019.10.006"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.65.4.577","article-title":"Levodopa responsive parkinsonism in an adult with Huntington\u2019s disease","volume":"65","author":"Racette","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200201000-00011","article-title":"Pramipexole Ameliorates Neurologic and Psychiatric Symptoms in a Westphal Variant of Huntington\u2019s Disease","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E004","article-title":"Amantadine in the Akinetic-Rigid Variant of Huntington\u2019s Disease","volume":"38","author":"Magnet","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.parkreldis.2015.01.002","article-title":"Rasagiline for the treatment of parkinsonism in Huntington\u2019s disease","volume":"21","author":"Pagonabarraga","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_152","first-page":"1","article-title":"Coexistence of Gait Disturbances and Chorea in Experimental Huntington\u2019s Disease","volume":"2015","author":"Temel","year":"2015","journal-title":"Behav. Neurol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Heikkinen, T., Bragge, T., Bhattarai, N., Parkkari, T., Puoliv\u00e4li, J., Kontkanen, O., Sweeney, P., Park, L.C., Munoz-Sanjuan, I., and Li, Y. (2020). Rapid and robust patterns of spontaneous locomotor deficits in mouse models of Huntington\u2019s disease. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243052"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Vuong, K., Canning, C.G., Menant, J.C., and Loy, C.T. (2018). Gait, balance, and falls in Huntington disease. Handbook of Clinical Neurology, Elsevier.","DOI":"10.1016\/B978-0-444-63916-5.00016-1"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1212\/WNL.0000000000008887","article-title":"Clinical recommendations to guide physical therapy practice for Huntington disease","volume":"94","author":"Quinn","year":"2020","journal-title":"Neurology"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Quinn, L., and Busse, M. (2017). The role of rehabilitation therapy in Huntington disease. Handbook of Clinical Neurology, Elsevier.","DOI":"10.1016\/B978-0-12-801893-4.00013-4"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0269215513487235","article-title":"Video game play (Dance Dance Revolution) as a potential exercise therapy in Huntington\u2019s disease: A controlled clinical trial","volume":"27","author":"Kloos","year":"2013","journal-title":"Clin. Rehabil."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0269215512473762","article-title":"What effect does a structured home-based exercise programme have on people with Huntington\u2019s disease? A randomized, controlled pilot study","volume":"27","author":"Khalil","year":"2013","journal-title":"Clin. Rehabil."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.gaitpost.2021.03.016","article-title":"Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntington\u2019s disease","volume":"86","author":"Kegelmeyer","year":"2021","journal-title":"Gait Posture"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Landwehrmeyer","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/mds.870120633","article-title":"Cortical myoclonus in huntington\u2019s disease associated with an enlarged somatosensory evoked potential","volume":"12","author":"Caviness","year":"1997","journal-title":"Mov. Disord."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Saft, C., Lauter, T., Kraus, P.H., Przuntek, H., and Andrich, J.E. (2006). Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington\u2019s Disease patients: A case series. BMC Neurol., 6.","DOI":"10.1186\/1471-2377-6-11"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.870100116","article-title":"Tourettism associated with Huntington\u2019s disease","volume":"10","author":"Jankovic","year":"1995","journal-title":"Mov. Disord."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10072-020-04265-0","article-title":"Management of dysphagia in Huntington\u2019s disease: A descriptive review","volume":"41","author":"Pizzorni","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archneur.1985.04060010063017","article-title":"Dysphagia in Huntington\u2019s Disease","volume":"42","author":"Leopold","year":"1985","journal-title":"Arch. Neurol."},{"key":"ref_166","first-page":"78","article-title":"Relationship between Nutritional Status and the Severity of Huntington\u2019s Disease. A Spanish Multicenter Dietary Intake Study","volume":"4","author":"Cubo","year":"2015","journal-title":"J. Huntingt. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.22953","article-title":"Cognitive and functional decline in Huntington\u2019s disease: Dementia criteria revisited","volume":"25","author":"Peavy","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.nicl.2020.102415","article-title":"Structural brain correlates of dementia in Huntington\u2019s disease","volume":"28","author":"Sampedro","year":"2020","journal-title":"NeuroImage Clin."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JHD-210469","article-title":"Cognitive and Affective Empathy in Huntington\u2019s Disease","volume":"10","author":"Sampedro","year":"2021","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Mason, S.L., Schaepers, M., and Barker, R.A. (2021). Problems with Social Cognition and Decision-Making in Huntington\u2019s Disease: Why Is it Important?. Brain Sci., 11.","DOI":"10.3390\/brainsci11070838"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5334\/tohm.231","article-title":"The Many Facets of Unawareness in Huntington Disease","volume":"4","author":"McCusker","year":"2014","journal-title":"Tremor Hyperkin. Mov."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1212\/WNL.0b013e3182a55f05","article-title":"Unawareness of motor phenoconversion in Huntington disease","volume":"81","author":"McCusker","year":"2013","journal-title":"Neurology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0b013e3181eccfa2","article-title":"Mild cognitive impairment in prediagnosed Huntington disease","volume":"75","author":"Duff","year":"2010","journal-title":"Neurology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cortex.2017.07.022","article-title":"A systematic linguistic profile of spontaneous narrative speech in pre-symptomatic and early stage Huntington\u2019s disease","volume":"100","author":"Hinzen","year":"2018","journal-title":"Cortex"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/acn3.70022","article-title":"Early Language Impairment as an Integral Part of the Cognitive Phenotype in Huntington\u2019s Disease","volume":"12","author":"Sampedro","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.30164","article-title":"Antidopaminergic Medications and Clinical Changes in Measures of Huntington\u2019s Disease: A Causal Analysis","volume":"40","author":"Geva","year":"2025","journal-title":"Mov. Disord."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease","volume":"19","author":"Specchio","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","article-title":"Two Years\u2019 Follow-up of Rivastigmine Treatment in Huntington Disease","volume":"30","author":"Difruscolo","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","article-title":"Rivastigmine in the treatment of Huntington\u2019s disease","volume":"9","author":"Rot","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"ref_180","first-page":"239","article-title":"Cognitive function in early clinical phase huntington disease after rivastigmine treatment","volume":"26","author":"Bolle","year":"2014","journal-title":"Psychiatr. Danub."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200401000-00010","article-title":"Treatment of Huntington\u2019s disease with galantamine","volume":"19","author":"Petrikis","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","article-title":"Donepezil for Huntington\u2019s disease","volume":"15","author":"Fernandez","year":"2000","journal-title":"Mov. Disord."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00213-008-1068-0","article-title":"The effects of modafinil on mood and cognition in Huntington\u2019s disease","volume":"199","author":"Blackwell","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Piira, A., van Walsem, M.R., Mikalsen, G., Nilsen, K.H., Knutsen, S., and Frich, J.C. (2013). Effects of a One Year Intensive Multidisciplinary Rehabilitation Program for Patients with Huntington\u2019s Disease: A Prospective Intervention Study. PLoS Curr., 5.","DOI":"10.1371\/currents.hd.9504af71e0d1f87830c25c394be47027"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e00312","DOI":"10.1002\/brb3.312","article-title":"The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington\u2019s disease: An exploratory study","volume":"5","author":"Cruickshank","year":"2015","journal-title":"Brain Behav."},{"key":"ref_187","first-page":"1","article-title":"A randomized clinical trial to evaluate the efficacy of cognitive rehabilitation and music therapy in mild cognitive impairment in Huntington\u2019s disease","volume":"272","author":"Kulisevsky","year":"2025","journal-title":"J. Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Molnar, M.J., Molnar, V., Fedor, M., Csehi, R., Acsai, K., Borsos, B., and Grosz, Z. (2022). Improving Mood and Cognitive Symptoms in Huntington\u2019s Disease With Cariprazine Treatment. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.825532"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1212\/WNL.49.1.153","article-title":"Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington\u2019s disease","volume":"49","author":"Murman","year":"1997","journal-title":"Neurology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e13852","DOI":"10.1111\/cts.13852","article-title":"Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington\u2019s disease","volume":"17","author":"Koenig","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_191","unstructured":"(2025, April 15). Available online: https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-topline-results-phase-2-dimension."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"HORIZON Investigators of the Huntington Study Group, and European Huntington\u2019s Disease Network (2013). A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease. JAMA Neurol., 70, 25.","DOI":"10.1001\/2013.jamaneurol.382"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","article-title":"Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington\u2019s Disease","volume":"33","author":"Lundin","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.25750","article-title":"Results of the citalopram to enhance cognition in Huntington disease trial","volume":"29","author":"Beglinger","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.870120319","article-title":"A controlled trial of fluoxetine in nondepressed patients with Huntington\u2019s disease","volume":"12","author":"Como","year":"1997","journal-title":"Mov. Disord."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY)","volume":"85","author":"Craufurd","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","article-title":"Longitudinal Psychiatric Symptoms in Prodromal Huntington\u2019s Disease: A Decade of Data","volume":"173","author":"Epping","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mds.22412","article-title":"Health-related quality of life in Huntington\u2019s disease: Which factors matter most?","volume":"24","author":"Ho","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Neuropsychiatric symptoms are very common in premanifest and early stage Huntington\u2019s Disease","volume":"25","author":"Carceller","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: The Integrated Staging System","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JHD-180293","article-title":"Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders","volume":"7","author":"Anderson","year":"2018","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Slaughter, J.R., Martens, M.P., and Slaughter, K.A. (2001). Depression and Huntington\u2019s Disease: Prevalence, Clinical Manifestations, Etiology, and Treatment. CNS Spectr., 6.","DOI":"10.1017\/S109285290002201X"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00702-024-02750-w","article-title":"The pathobiology of depression in Huntington\u2019s disease: An unresolved puzzle","volume":"131","author":"Jellinger","year":"2024","journal-title":"J. Neural Transm."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.neuropsych.20230120","article-title":"Treatment of Depression in Huntington\u2019s Disease: A Systematic Review","volume":"36","author":"Zadegan","year":"2024","journal-title":"J. Neuropsychiatry"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington\u2019s disease","volume":"23","author":"Phillips","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","article-title":"Combating depression in Huntington\u02bcs disease: Effective antidepressive treatment with venlafaxine XR","volume":"25","author":"Holl","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1176\/jnp.8.3.338","article-title":"Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease","volume":"8","author":"Ranen","year":"1996","journal-title":"J. Neuropsychiatry"},{"key":"ref_208","first-page":"216","article-title":"Obsessive compulsive disorder in huntington disease: A case of isolated obsessions successfully treated with sertraline","volume":"15","author":"Patzold","year":"2002","journal-title":"Cogn. Behav. Neurol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1345\/aph.1C352","article-title":"Mirtazapine in Suicidal Huntington\u2019s Disease","volume":"37","author":"Bonelli","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15622970701332520","article-title":"Lamotrigine in motor and mood symptoms of Huntington\u2019s disease","volume":"9","author":"Shen","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/JCP.0b013e31829c9748","article-title":"Lithium Treatment in Patients With Huntington Disease and Suicidal Behavior","volume":"33","author":"Raja","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JHD-190361","article-title":"Electroconvulsive Therapy (ECT) for Refractory Psychiatric Symptoms in Huntington\u2019s Disease: A Case Series and Review of the Literature","volume":"8","author":"Adrissi","year":"2019","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"678.e3","DOI":"10.1016\/j.genhosppsych.2013.01.015","article-title":"Rapid improvement of depression and psychotic symptoms in Huntington\u2019s disease: A retrospective chart review of seven patients treated with electroconvulsive therapy","volume":"35","author":"Cusin","year":"2013","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1176\/jnp.6.2.154","article-title":"ECT as a treatment for depression in Huntington\u2019s disease","volume":"6","author":"Ranen","year":"1994","journal-title":"JNP"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/hmg\/ddq512","article-title":"Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice","volume":"20","author":"Mughal","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","article-title":"Neuropsychiatric aspects of Huntington\u2019s disease","volume":"71","author":"Paulsen","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mdc3.13147","article-title":"Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington\u2019s Disease","volume":"8","author":"Atkins","year":"2021","journal-title":"Mov. Disord. Clin. Pr."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.parkreldis.2022.10.025","article-title":"Delineating apathy profiles in Huntington\u2019s disease with the short-Lille Apathy Rating Scale","volume":"105","author":"Perez","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1176\/appi.neuropsych.21070191","article-title":"Apathy and Depression in Huntington\u2019s Disease: Distinct Longitudinal Trajectories and Clinical Correlates","volume":"35","author":"Connors","year":"2023","journal-title":"J. Neuropsychiatry"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cercor\/bhj043","article-title":"Apathy and the Functional Anatomy of the Prefrontal Cortex\u2013Basal Ganglia Circuits","volume":"16","author":"Levy","year":"2006","journal-title":"Cereb. Cortex"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/mds.27395","article-title":"Structural and metabolic brain correlates of apathy in Huntington\u2019s disease","volume":"33","author":"Sampedro","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.nicl.2019.101965","article-title":"White matter cortico-striatal tracts predict apathy subtypes in Huntington\u2019s disease","volume":"24","author":"Sierpowska","year":"2019","journal-title":"NeuroImage Clin."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Gelderblom, H., W\u00fcstenberg, T., McLean, T., M\u00fctze, L., Fischer, W., Saft, C., Hoffmann, R., S\u00fcssmuth, S., Schlattmann, P., and van Duijn, E. (2017). Bupropion for the treatment of apathy in Huntington\u2019s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173872"},{"key":"ref_225","first-page":"1","article-title":"Aripiprazole in the treatment of Huntington\u2019s disease: A case series","volume":"5","author":"Sassone","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_226","first-page":"107","article-title":"Structural brain correlates of irritability and aggression in early manifest Huntington\u2019s disease","volume":"15","author":"Sampedro","year":"2020","journal-title":"Brain Imaging Behav."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1002\/hbm.22799","article-title":"Functional brain changes underlying irritability in premanifest Huntington\u2019s disease","volume":"36","author":"Stock","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psychres.2012.09.022","article-title":"Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington\u2019s disease","volume":"207","author":"Labuschagne","year":"2013","journal-title":"Psychiatry Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s002130000575","article-title":"Fluoxetine in the treatment of Huntington\u2019s disease","volume":"153","author":"Daniele","year":"2001","journal-title":"Psychopharmacology"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-010-0088-3","article-title":"Treatment of Irritability in Huntington\u2019s Disease","volume":"12","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/0019-5545.74318","article-title":"How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy","volume":"52","author":"Andrade","year":"2010","journal-title":"Indian J. Psychiatry"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the Treatment of Behavioral Disturbances in Patients With Huntington\u2019s Disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington\u2019s disease: Olanzapine in Huntington\u2019s disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol. Scand."},{"key":"ref_234","first-page":"548","article-title":"Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study","volume":"40","author":"Habibi","year":"2015","journal-title":"Iran. J. Med. Sci."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3233\/JHD-140127","article-title":"Aggression in Huntington\u2019s Disease: A Systematic Review of Rates of Aggression and Treatment Methods","volume":"3","author":"Fisher","year":"2014","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Brownstein, M.J., Simon, N.G., Long, J.D., Yankey, J., Maibach, H.T., Cudkowicz, M., Coffey, C., Conwit, R.A., Lungu, C., and Anderson, K.E. (2020). Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington\u2019s Disease Patients\u2014A Randomized Phase 2 Clinical Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113682"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Maibach, H.T., Brownstein, M.J., Hersch, S.M., Anderson, K.E., Itzkowitz, D.E., Damiano, E.M., and Simon, N.G. (2022). The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington\u2019s Disease. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101561"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1212\/WNL.0000000000208191","article-title":"A Pilot Study to Evaluate the Efficacy of Dextromethorphan\/Quinidine in Treating Irritability in Huntington\u2019s Disease (P6-3.008)","volume":"102","author":"Zadegan","year":"2024","journal-title":"Neurology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-180335","article-title":"Obsessive-Compulsive and Perseverative Behaviors in Huntington\u2019s Disease","volume":"8","author":"Oosterloo","year":"2019","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_240","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Cogn. Behav. Neurol."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Anderson, K., Craufurd, D., Edmondson, M.C., Goodman, N., Groves, M., van Duijn, E., van Kammen, D.P., and Goodman, L. (2011). An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington\u2019s Disease. PLoS Curr., 3.","DOI":"10.1371\/currents.RRN1261"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5334\/tohm.395","article-title":"Understanding HD Psychosis: An Analysis from the ENROLL-HD Database","volume":"10","author":"Jaini","year":"2020","journal-title":"Tremor Other Hyperkinetic Mov."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Rocha, N.P., Mwangi, B., Candano, C.A.G., Sampaio, C., Stimming, E.F., and Teixeira, A.L. (2018). The Clinical Picture of Psychosis in Manifest Huntington\u2019s Disease: A Comprehensive Analysis of the Enroll-HD Database. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00930"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp-2019-320646","article-title":"Psychosis and longitudinal outcomes in Huntington disease: The COHORT Study","volume":"91","author":"Connors","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/jnnp.47.12.1283","article-title":"Increased rate of suicide among patients with Huntington\u2019s disease","volume":"47","author":"Schoenfeld","year":"1984","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.30.4.293","article-title":"Suicide risk in Huntington\u2019s disease","volume":"30","author":"Squitieri","year":"1993","journal-title":"J. Med Genet."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000079953","article-title":"Suicide in Hungarian Huntington\u2019s Disease Patients","volume":"23","author":"Baliko","year":"2004","journal-title":"Neuroepidemiology"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000327754","article-title":"PREDICT-HD Investigators of the Huntington Study Group. Suicidal Behavior in Prodromal Huntington Disease","volume":"8","author":"Fiedorowicz","year":"2011","journal-title":"Neurodegener Dis."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JHD-180299","article-title":"Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease","volume":"7","author":"Wesson","year":"2018","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1192\/bjo.2021.969","article-title":"Incidence of completed suicide and suicide attempts in a global prospective study of Huntington\u2019s disease","volume":"7","author":"Fernandes","year":"2021","journal-title":"BJPsych Open"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archneur.65.4.482","article-title":"Rapid Eye Movement Sleep Disturbances in Huntington Disease","volume":"65","author":"Arnulf","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.parkreldis.2017.09.013","article-title":"Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington\u2019s disease","volume":"44","author":"Kulisevsky","year":"2017","journal-title":"Park. Relat. Disord."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:00:34Z","timestamp":1760032834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":252,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136220"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136220","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}